Acute Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major acute pharyngitis markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.7% during 2024-2034.
The acute pharyngitis market has been comprehensively analyzed in IMARC's new report titled "Acute Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute pharyngitis, commonly known as a sore throat, refers to an inflammation of the pharynx, the area at the back of the throat. This disorder can be caused by viral or bacterial infections, environmental factors, or irritants. The condition is characterized by symptoms, such as soreness, scratchiness, or pain in the throat, especially when swallowing. It often accompanies indications like coughing, sneezing, a runny nose, and occasionally, fever. The diagnosis of acute pharyngitis involves a combination of clinical evaluation and, in some cases, diagnostic tests. The healthcare providers typically begin by examining the patient's throat for redness, swelling, or pus on the tonsils. They may also inquire about the duration and severity of the symptoms. If a bacterial infection is suspected, a rapid strep test might be performed to detect the presence of Streptococcus bacteria. In some instances, a throat culture might be sent to a laboratory for more accurate identification of the causative agent.
The rising cases of bacterial and viral infections, in which the pathogen invades the mucosal tissues of the pharynx directly, causing inflammation and irritation, are primarily driving the acute pharyngitis market. In addition to this, the inflating utilization of effective antibiotics like penicillin, cephalosporins, macrolides, etc., to combat bacterial cases of the condition is also creating a positive outlook for the market. These therapeutic agents work by inhibiting the synthesis of bacterial cell walls and preventing bacterial replication and proliferation in patients. Moreover, the widespread adoption of symptomatic treatments, such as analgesics and throat lozenges, which provide relief from pain and inflammation, is further fueling the market growth. Apart from this, the increasing awareness and utilization of salt-water gargling, humidifiers, and hydration therapies to improve treatment outcomes in individuals suffering from the disorder are acting as another significant growth-inducing factor. Additionally, the escalating demand for rapid antigen tests, since they are specifically designed to diagnose streptococcal pharyngitis promptly, is also augmenting the market growth. Furthermore, numerous advancements in immunization against some causative pathogens, including the influenza virus and Streptococcus pneumoniae, to prevent the contraction of the disease are expected to drive the acute pharyngitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute pharyngitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute pharyngitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute pharyngitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute pharyngitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute pharyngitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute pharyngitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute pharyngitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute pharyngitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute pharyngitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute pharyngitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pharyngitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pharyngitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acute pharyngitis across the seven major markets?
What is the size of the acute pharyngitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute pharyngitis?
What will be the growth rate of patients across the seven major markets?
Acute Pharyngitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute pharyngitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute pharyngitis market?
What are the key regulatory events related to the acute pharyngitis market?
What is the structure of clinical trial landscape by status related to the acute pharyngitis market?
What is the structure of clinical trial landscape by phase related to the acute pharyngitis market?
What is the structure of clinical trial landscape by route of administration related to the acute pharyngitis market?
The acute pharyngitis market has been comprehensively analyzed in IMARC's new report titled "Acute Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute pharyngitis, commonly known as a sore throat, refers to an inflammation of the pharynx, the area at the back of the throat. This disorder can be caused by viral or bacterial infections, environmental factors, or irritants. The condition is characterized by symptoms, such as soreness, scratchiness, or pain in the throat, especially when swallowing. It often accompanies indications like coughing, sneezing, a runny nose, and occasionally, fever. The diagnosis of acute pharyngitis involves a combination of clinical evaluation and, in some cases, diagnostic tests. The healthcare providers typically begin by examining the patient's throat for redness, swelling, or pus on the tonsils. They may also inquire about the duration and severity of the symptoms. If a bacterial infection is suspected, a rapid strep test might be performed to detect the presence of Streptococcus bacteria. In some instances, a throat culture might be sent to a laboratory for more accurate identification of the causative agent.
The rising cases of bacterial and viral infections, in which the pathogen invades the mucosal tissues of the pharynx directly, causing inflammation and irritation, are primarily driving the acute pharyngitis market. In addition to this, the inflating utilization of effective antibiotics like penicillin, cephalosporins, macrolides, etc., to combat bacterial cases of the condition is also creating a positive outlook for the market. These therapeutic agents work by inhibiting the synthesis of bacterial cell walls and preventing bacterial replication and proliferation in patients. Moreover, the widespread adoption of symptomatic treatments, such as analgesics and throat lozenges, which provide relief from pain and inflammation, is further fueling the market growth. Apart from this, the increasing awareness and utilization of salt-water gargling, humidifiers, and hydration therapies to improve treatment outcomes in individuals suffering from the disorder are acting as another significant growth-inducing factor. Additionally, the escalating demand for rapid antigen tests, since they are specifically designed to diagnose streptococcal pharyngitis promptly, is also augmenting the market growth. Furthermore, numerous advancements in immunization against some causative pathogens, including the influenza virus and Streptococcus pneumoniae, to prevent the contraction of the disease are expected to drive the acute pharyngitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the acute pharyngitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for acute pharyngitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute pharyngitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the acute pharyngitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the acute pharyngitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current acute pharyngitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the acute pharyngitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the acute pharyngitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the acute pharyngitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of acute pharyngitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pharyngitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of acute pharyngitis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with acute pharyngitis across the seven major markets?
What is the size of the acute pharyngitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of acute pharyngitis?
What will be the growth rate of patients across the seven major markets?
Acute Pharyngitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for acute pharyngitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute pharyngitis market?
What are the key regulatory events related to the acute pharyngitis market?
What is the structure of clinical trial landscape by status related to the acute pharyngitis market?
What is the structure of clinical trial landscape by phase related to the acute pharyngitis market?
What is the structure of clinical trial landscape by route of administration related to the acute pharyngitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE PHARYNGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE PHARYNGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE PHARYNGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACUTE PHARYNGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE PHARYNGITIS - UNMET NEEDS
10 ACUTE PHARYNGITIS - KEY ENDPOINTS OF TREATMENT
11 ACUTE PHARYNGITIS - MARKETED PRODUCTS
11.1 List of Acute Pharyngitis Marketed Drugs Across the Top 7 Markets
11.1.1 Zithromax (Azithromycin) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Suprax (Cefixime) - Lupin
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE PHARYNGITIS - PIPELINE DRUGS
12.1 List of Acute Pharyngitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ACUTE PHARYNGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE PHARYNGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE PHARYNGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Pharyngitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Pharyngitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Pharyngitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Pharyngitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Pharyngitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Pharyngitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Pharyngitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Pharyngitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Pharyngitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Pharyngitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Pharyngitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Pharyngitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Pharyngitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Pharyngitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Pharyngitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Pharyngitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Pharyngitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Pharyngitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Pharyngitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Pharyngitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Pharyngitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Pharyngitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Pharyngitis - Access and Reimbursement Overview
16 ACUTE PHARYNGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE PHARYNGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE PHARYNGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ACUTE PHARYNGITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ACUTE PHARYNGITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ACUTE PHARYNGITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ACUTE PHARYNGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ACUTE PHARYNGITIS - UNMET NEEDS
10 ACUTE PHARYNGITIS - KEY ENDPOINTS OF TREATMENT
11 ACUTE PHARYNGITIS - MARKETED PRODUCTS
11.1 List of Acute Pharyngitis Marketed Drugs Across the Top 7 Markets
11.1.1 Zithromax (Azithromycin) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Suprax (Cefixime) - Lupin
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ACUTE PHARYNGITIS - PIPELINE DRUGS
12.1 List of Acute Pharyngitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ACUTE PHARYNGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ACUTE PHARYNGITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ACUTE PHARYNGITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Acute Pharyngitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Acute Pharyngitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Acute Pharyngitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Acute Pharyngitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Acute Pharyngitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Acute Pharyngitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Acute Pharyngitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Acute Pharyngitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Acute Pharyngitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Acute Pharyngitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Acute Pharyngitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Acute Pharyngitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Acute Pharyngitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Acute Pharyngitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Acute Pharyngitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Acute Pharyngitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Acute Pharyngitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Acute Pharyngitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Acute Pharyngitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Acute Pharyngitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Acute Pharyngitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Acute Pharyngitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Acute Pharyngitis - Access and Reimbursement Overview
16 ACUTE PHARYNGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ACUTE PHARYNGITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ACUTE PHARYNGITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
